Research and Development (R&D)

Key Takeaways •The POETYK PSO long-term extension trial demonstrated that Sotyktu maintains a consistent safety profile over five years.•Clinical responses, including PASI 90, were sustained...

Key TakeawaysCosmos Health secures exclusive licensing and buy-out rights for two innovative anticancer drugs, targeting prostate, ovarian, and colorectal cancers. The drugs are...

Key TakeawaysENA Respiratory has successfully completed Phase Ib dosing of its INNA-051 dry powder formulation in older adults aged 60+, demonstrating safety and...

Key TakeawaysJaguar Health has initiated an investigator-initiated trial (IIT) for crofelemer in microvillus inclusion disease (MVID). The study is being conducted at Sheikh...

Key TakeawaysThe European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Bristol Myers Squibb's CAR T...

Key Takeaways •BioDuro has inaugurated a state-of-the-art solid-phase peptide synthesis scale-up facility in Shanghai, enhancing its capacity to meet the growing global demand for efficient...

  Key Takeaways •Akero Therapeutics’ efruxifermin (EFX) demonstrated significant histological improvements in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in the Phase 2b HARMONY study.•After 96...

Key TakeawaysMainz Biomed begins the eAArly DETECT 2 feasibility study to evaluate its advanced colorectal cancer (CRC) diagnostic test. The study will involve...

Key TakeawaysSTRIDES Phase 2 trial for azelaprag in obesity treatment discontinued due to observed liver transaminitis. Company to assess data and announce updated...

Key TakeawaysBemnifosbuvir and ruzasvir regimen achieved 98% sustained virologic response (SVR12) in Phase 2 study. The treatment was well-tolerated with no serious adverse...

Key TakeawaysZetaMAST™ shows fourfold tumor volume reduction in liver metastases. Survival rates improved by nearly 4x over standard treatment. Zetagen plans to advance...

Key TakeawaysCytomos raises £5 million to scale its AuraCyt™ cell analysis platform and commercialize Celledonia™. AuraCyt™ enables biopharma companies to develop therapies faster...

Key TakeawaysWRAPSODY achieves 82% target lesion primary patency at six months, exceeding performance goals. The WAVE trial highlights significant improvements in vascular access...

Key TakeawaysThe 2024 San Antonio Breast Cancer Symposium (SABCS) will host nearly 11,000 participants. Researchers, healthcare professionals, and advocates will present the latest...

Key TakeawaysDZP achieved a 14.6% higher BICLA response rate at 48 weeks compared to SOC alone. Participants on DZP experienced a 50% reduction...